A systematic review of treatment for patients with burning mouth syndrome

Huann Lan Tan, Jared G Smith, Jan Hoffmann, Tara Renton, Huann Lan Tan, Jared G Smith, Jan Hoffmann, Tara Renton

Abstract

Background: Burning mouth syndrome is a chronic idiopathic intractable intraoral dysaesthesia that remains a challenge to clinicians due to its poorly understood pathogenesis and inconsistent response to various treatments.

Aim: This review aimed to study the short- (≤3 months) and long-term (>3 months) effectiveness and sustainable benefit of different burning mouth syndrome treatment strategies and the associated side effects.

Materials and methods: Randomised controlled trials of burning mouth syndrome treatment compared with placebo or other interventions with a minimum follow up of 2 months were searched from the PubMed, Embase and Cochrane database (published to July 2020).

Results: Twenty-two studies were selected based on the inclusion and exclusion criteria and analysed. Nine categories of burning mouth syndrome treatment were identified: Anticonvulsant and antidepressant agents, phytomedicine and alpha lipoic acid supplements, low-level laser therapy, saliva substitute, transcranial magnetic stimulation, and cognitive behaviour therapy. Cognitive behaviour therapy, topical capsaicin and clonazepam, and laser therapy demonstrated favourable outcome in both short- and long-term assessment. Phytomedicines reported a short-term benefit in pain score reduction. The pooled effect of alpha lipoic acid (ALA) pain score improvement was low, but its positive effects increased in long term assessment.

Conclusion: A more significant volume in terms of sample size, multi-centres, and multi-arm comparison of therapeutic agents with placebo and longitudinal follow-up studies is recommended to establish a standardised burning mouth syndrome treatment protocol. Further studies are required to assess the analgesic benefits of topical clonazepam and capsaicin, alternative medicines with neurodegenerative prevention capability and psychology support in treating burning mouth syndrome and reducing systemic adverse drug reactions.Registration International Prospective Register of Systematic Reviews (PROSPERO):Protocol ID - CRD42020160892.

Keywords: Burning mouth syndrome; glossodynia; systematic review; treatment.

Conflict of interest statement

Declaration of conflicting interests: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: HLT, JGS and TR declare no potential conflicts of interest with respect to the research, authorship and/or publication of this article. JH is consulting for and/or serves on the advisory boards of AdCel Biopharma, Allergan, Autonomic Technologies Inc., Cannovex BV, Chordate Medical AB, Eli Lilly, Hormosan Pharma, Lundbeck, Novartis, Sanofi and Teva. He has received honoraria for speaking from Allergan, Autonomic Technologies Inc., Chordate Medical AB, Lundbeck, Novartis and Teva. He received personal fees for Medico-Legal Work as well as from Oxford University Press, Quintessence Publishing, Sage Publishing and Springer Healthcare. He receives research support from Bristol-Myers-Squibb. All these activities are unrelated to the submitted work.

Figures

Figure 1.
Figure 1.
Flow chart on the study selection process (adapted from PRIMA, 2009).
Figure 2.
Figure 2.
Forest plot showing standardised mean differences (SMD) and 95% confidence intervals for short-term outcomes (≥2 months and ≤3 months) of RCTs comparing an intervention with placebo for the treatment of BMS (with separate pooled effects for ALA).
Figure 3.
Figure 3.
Forest plot showing standardised mean differences (SMD) and 95% confidence intervals for long-term outcomes (>3 months) of RCTs comparing an intervention with placebo for the treatment of BMS (with separate pooled effects for ALA).
Figure 4.
Figure 4.
Forest plot showing relative risks (RRs) and 95% confidence intervals for short-term outcomes (improvement on VAS at ≤3 months) of RCTs comparing an intervention with placebo for the treatment of BMS (with pooled effect for ALA).
Figure 5.
Figure 5.
Forest plot showing relative risks (RRs) and 95% confidence intervals for long-term outcomes (improvement on VAS at >3 months) of RCTs comparing an intervention with placebo for the treatment of BMS (with pooled effect for ALA).

References

    1. International Classification of Orofacial Pain, 1st edition (ICOP). Cephalalgia 2020; 40(2): 129-221.
    1. Kohorst JJ, Bruce AJ, Torgerson RR, et al.. The prevalence of burning mouth syndrome: A population-based study. Br J Dermatol 2015; 172: 1654–1656.
    1. Bergdahl M, Bergdahl J. Burning mouth syndrome: Prevalence and associated factors. J Oral Pathol Med 1999; 28: 350–354.
    1. Scala A, Checchi L, Montevecchi M, et al.. Update on burning mouth syndrome: Overview and patient management. Crit Rev Oral Biol Med 2003; 14: 275–291.
    1. Forssell H, Teerijoki-Oksa T, Kotiranta U, et al. . Pain and pain behavior in burning mouth syndrome: A pain diary study. J Orofac Pain 2012; 26: 117–125.
    1. Schiavone V, Adamo D, Ventrella G, et al.. Anxiety, depression, and pain in burning mouth syndrome: First chicken or egg? Headache 2012; 52: 1019–1025.
    1. Jääskeläinen SK, Woda A. Burning mouth syndrome. Cephalalgia 2017; 37: 627–647.
    1. Sardella A, Lodi G, Demarosi F, et al.. Burning mouth syndrome: A retrospective study investigating spontaneous remission and response to treatments. Oral Dis 2006; 12: 152–155.
    1. Liu YF, Kim Y, Yoo T, et al.. Burning mouth syndrome: A systematic review of treatments. Oral Dis 2018; 24: 325–334.
    1. De Souza IF, Mármora BC, Rados PV, et al.. Treatment modalities for burning mouth syndrome: A systematic review. Clin Oral Investig 2018; 22: 1893–1905.
    1. McMillan R, Forssell H, Buchanan JA, et al.. Interventions for treating burning mouth syndrome. Cochrane Database Syst Rev 2016; 11: CD002779.
    1. Moher D, Liberati A, Tetzlaff J, et al.. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009; 6: e1000097.
    1. Higgins JP, Altman DG, Gøtzsche PC, et al.; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
    1. Brozek JL, Akl EA, Alonso-Coello P, et al.. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 2009; 64: 669–677.
    1. Altman DG, Dore CJ. Randomisation and baseline comparisons in clinical trials. Lancet 1990; 335: 149–153.
    1. Pagano M, Gauvreau K. Principles of biostatistics, 2nd edn. Belmont, CA: Brooks/Cole, 2000, p.592.
    1. Deeks JJ, Higgins JPT. Statistical algorithms in Review Manager 5 2010, (2010, accessed 3 January 2021).
    1. Varoni EM, Lo Faro AF, Lodi G, et al.. Melatonin treatment in patients with burning mouth syndrome: A triple-blind, placebo-controlled, crossover randomized clinical trial. J Oral Facial Pain Headache 2018; 32: 178–188.
    1. De Rivera Campillo ER, López-López J, Chimenos-Küstner E. Response to topical clonazepam in patients with burning mouth syndrome: A clinical study. Bull Group Int Rech Sci Stomatol Odontol 2010; 49: 19–29.
    1. Heckmann SM, Kirchner E, Grushka M, et al.. A double-blind study on clonazepam in patients with burning mouth syndrome. Laryngoscope 2012; 122: 813–816.
    1. Tammiala-Salonen T, Forssell H. Trazodone in burning mouth pain: A placebo-controlled, double-blind study. J Orofac Pain 1999; 13: 83–88.
    1. Femiano F, Scully C. Burning mouth syndrome (BMS): Double blind controlled study of alpha-lipoic acid (thioctic acid) therapy. J Oral Pathol Med 2002; 31: 267–269.
    1. Carbone M, Pentenero M, Carrozzo M, et al.. Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: A double-blind, randomized, placebo-controlled study. Eur J Pain 2009; 13: 492–496.
    1. López-Jornet P, Camacho-Alonso F, Leon-Espinosa S. Efficacy of alpha lipoic acid in burning mouth syndrome: A randomized, placebo-treatment study. J Oral Rehabil 2009; 36: 52–57.
    1. López-D'alessandro E, Escovich L. Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: A randomized, double-blind, placebo controlled trial. Med Oral Patol Oral Cir Bucal 2011; 16: e635– e640.
    1. Palacios-Sánchez B, Moreno-López LA, Cerero-Lapiedra R, et al.. Alpha lipoic acid efficacy in burning mouth syndrome. A controlled clinical trial. Med Oral Patol Oral Cir Bucal 2015; 20: e435– e440.
    1. Cano-Carrillo P, Pons-Fuster A, López-Jornet P. Efficacy of lycopene-enriched virgin olive oil for treating burning mouth syndrome: A double-blind randomised. J Oral Rehabil 2014; 41: 296–305.
    1. Sardella A, Lodi G, Demarosi F, et al.. Hypericum perforatum extract in burning mouth syndrome: A randomized placebo-controlled study. J Oral Pathol Med 2008; 37: 395–401.
    1. Spanemberg JC, Cherubini K, De Figueiredo MA, et al.. Effect of an herbal compound for treatment of burning mouth syndrome: Randomized, controlled, double-blind clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 113: 373–377.
    1. Pakfetrat A, Talebi M, Dalirsani Z, et al. . Evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: A randomized controlled trial. Avicenna J Phytomed 2019; 9: 505–516.
    1. Ottaviani G, Rupel K, Gobbo M, et al.. Efficacy of ultramicronized palmitoylethanolamide in burning mouth syndrome-affected patients: A preliminary randomized double-blind controlled trial. Clin Oral Investig 2019; 23: 2743–2750.
    1. De Silva LA, Siqueira JT, Teixeira MJ, et al.. The role of xerostomia in burning mouth syndrome: A case-control study. Arq Neuropsiquiatr 2014; 72: 91–98.
    1. Marino R, Torretta S, Capaccio P, et al.. Different therapeutic strategies for burning mouth syndrome: Preliminary data. J Oral Pathol Med 2010; 39: 611–616.
    1. Spanemberg JC, López López J, De Figueiredo MA, et al.. Efficacy of low-level laser therapy for the treatment of burning mouth syndrome: A randomized, controlled trial. J Biomed Opt 2015; 20: 098001.
    1. Umezaki Y, Badran BW, DeVries WH, et al.. The efficacy of daily prefrontal repetitive transcranial magnetic stimulation (rTMS) for burning mouth syndrome (BMS): A randomized controlled single-blind study. Brain Stimul 2016; 9: 234–242.
    1. De Pedro M, López-Pintor RM, Casañas E, et al.. Effects of photobiomodulation with low-level laser therapy in burning mouth syndrome: A randomized clinical trial. Oral Dis 2020; 26: 1764–1776.
    1. Bergdahl J, Anneroth G, Perris H. Cognitive therapy in the treatment of patients with resistant burning mouth syndrome: A controlled study. J Oral Pathol Med 1995; 24: 213–215.
    1. López-Jornet P, Camacho-Alonso F, Andujar-Mateos P. A. prospective, randomized study on the efficacy of tongue protector in patients with burning mouth syndrome. Oral Dis 2011; 17: 277–282.
    1. Çınar SL, Kartal D, Pergel Tet al.. Effectiveness and safety of clonazepam, pregabalin, and alpha lipoic acid for the treatment of burning mouth syndrome. Erciyes Med J 2018; 40: 35–38.
    1. Imamura Y, Shinozaki T, Okada-Ogawa A, et al.. An updated review on pathophysiology and management of burning mouth syndrome with endocrinological, psychological and neuropathic perspectives. J Oral Rehabil 2019; 46: 574–587.
    1. Galli F, Lodi G, Sardella A, et al.. Role of psychological factors in burning mouth syndrome: A systematic review and meta-analysis. Cephalalgia 2017; 37: 265–277.
    1. Jääskeläinen SK. Pathophysiology of primary burning mouth syndrome. Clin Neurophysiol 2012; 123: 71–77.
    1. Kim JY, Kim YS, Ko I, et al.. Association between burning mouth syndrome and the development of depression, anxiety, dementia, and Parkinson disease. JAMA Otolaryngol Head Neck Surg 2020; 146: 561–569.
    1. Griffin CE, 3rd, Kaye AM, Bueno FR, et al.. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J 2013; 13: 214–223.
    1. Bartoshuk LM, Snyder DJ, Grushka M, et al.. Taste damage: Previously unsuspected consequences. Chem Senses 2005; 30: i218–i219.
    1. Gremeau-Richard C, Woda A, Navez ML, et al.. Topical clonazepam in stomatodynia: A randomised placebo-controlled study. Pain 2004; 108: 51–57.
    1. Fenelon M, Quinque E, Arrive E, et al.. Pain-relieving effects of clonazepam and amitriptyline in burning mouth syndrome: A retrospective study. Int J Oral Maxillofac Surg 2017; 46: 1505–1511.
    1. Wiffen PJ, Derry S, Bell RF, et al.. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017; 6: CD007938.
    1. Takasusuki T, Yaksh TL. The effects of intrathecal and systemic gabapentin on spinal substance P release. Anesth Analg 2011; 112: 971–976.
    1. Quintero JE, Dooley DJ, Pomerleau F, et al.. Amperometric measurement of glutamate release modulation by gabapentin and pregabalin in rat neocortical slices: Role of voltage-sensitive Ca2+ α2δ-1 subunit. J Pharmacol Exp Ther 2011; 338: 240–245.
    1. Khan SA, Keaser ML, Meiller TF, et al.. Altered structure and function in the hippocampus and medial prefrontal cortex in patients with burning mouth syndrome. Pain 2014; 155: 1472–1480.
    1. Yang G, Su S, Jie H, et al.. Somatosensory profiling of patients with burning mouth syndrome and correlations with psychologic factors. J Oral Facial Pain Headache 2019; 33: 278–286.
    1. Zorumski CF, Paul SM, Covey DF, et al.. Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond. Neurobiol Stress 2019; 11: 100196.
    1. Morillas-Arques P, Rodriguez-Lopez CM, Molina-Barea R, et al.. Trazodone for the treatment of fibromyalgia: An open-label, 12-week study. BMC Musculoskelet Disord 2010; 11: 204.
    1. Patetsos E, Horjales-Araujo E. Treating chronic pain with SSRIs: What do we know? Pain Res Manag 2016; 2016: 2020915.
    1. Dharmshaktu P, Tayal V, Kalra BS. Efficacy of antidepressants as analgesics: A review. J Clin Pharmacol 2012; 52: 6–17.
    1. World Health Organization. WHO global report on traditional and complementary medicine. Geneva: WHO, 2019, p.226.
    1. Khan H. Brilliant future of phytomedicines in the light of latest technological developments. J Phytopharmacol 2015; 4: 58–60.
    1. Pan YZ, Pan HL. Primary afferent stimulation differentially potentiates excitatory and inhibitory inputs to spinal lamina II outer and inner neurons. J Neurophysiol 2004; 91: 2413–2421.
    1. Yilmaz Z, Renton T, Yiangou Y, et al.. Burning mouth syndrome as a trigeminal small fibre neuropathy: Increased heat and capsaicin receptor TRPV1 in nerve fibres correlates with pain score. J Clin Neurosci 2007; 14: 864–871.
    1. Gamse R, Petsche U, Lembeck F, et al.. Capsaicin applied to peripheral nerve inhibits axoplasmic transport of substance P and somatostatin. Brain Res 1982; 239: 447–462.
    1. Anand P, Bley K. Topical capsaicin for pain management: Therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011; 107: 490–502.
    1. Nolano M, Simone DA, Wendelschafer-Crabb G, et al.. Topical capsaicin in humans: Parallel loss of epidermal nerve fibers and pain sensation. Pain 1999; 81: 135–145.
    1. Derry S, Rice AS, Cole P, et al.. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017; 1: CD007393.
    1. Maihofner C, Heskamp ML. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: First results of the QUEPP study. Curr Med Res Opin 2013; 29: 673–683.
    1. Mou J, Paillard F, Turnbull B, et al.. Efficacy of Qutenza® (capsaicin) 8% patch for neuropathic pain: A meta-analysis of the Qutenza Clinical Trials Database. Pain 2013; 154: 1632–1639.
    1. Altman RD, Barthel HR. Topical therapies for osteoarthritis. Drugs 2011; 71: 1259–1279.
    1. Petruzzi M, Lauritano D, De Benedittis M, et al.. Systemic capsaicin for burning mouth syndrome: Short-term results of a pilot study. J Oral Pathol Med 2004; 33: 111–114.
    1. Jensen TS, Høye K, Fricová J, et al.. Tolerability of the capsaicin 8% patch following pretreatment with lidocaine or tramadol in patients with peripheral neuropathic pain: A multicentre, randomized, assessor-blinded study. Eur J Pain 2014; 18: 1240–1247.
    1. Skaper SD. Impact of inflammation on the blood-neural barrier and blood-nerve interface: From review to therapeutic preview. Int Rev Neurobiol 2017; 137: 29–45.
    1. Scuderi C, Bronzuoli MR, Facchinetti R, et al.. Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer’s disease by exerting anti-inflammatory and neuroprotective effects. Transl Psychiatry 2018; 8: 32.
    1. Passavanti MB, Fiore M, Sansone P, et al.. The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: A pilot study comparing prospective and retrospective observational arms. BMC Anesthesiol 2017; 17: 171.
    1. Artukoglu BB, Beyer C, Zuloff-Shani A, et al. . Efficacy of Palmitoylethanolamide for pain: A meta-analysis. Pain Physician 2017; 20: 353–362.
    1. Paladini A, Fusco M, Cenacchi T, et al.. Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: A pooled data meta-analysis. Pain Physician 2016; 19: 11–24.
    1. Cocito D, Peci E, Ciaramitaro P, et al.. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Res Treat 2014; 2014: 854560.
    1. Quintão NL, Ferreira J, Beirith A, et al.. Evaluation of the effects of the herbal product Catuama in inflammatory and neuropathic models of nociception in rats. Phytomedicine 2008; 15: 245–252.
    1. Coppock RW, Dziwenka M. Chapter 45 – St. John’s Wort. In: Gupta RC (ed) Nutraceuticals. Amsterdam: Academic Press/Elsevier, 2016, pp.619–631.
    1. Müller WE, Rolli M, Schäfer C, et al.. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997; 30: 102–107.
    1. McCarson KE, Enna SJ. GABA pharmacology: The search for analgesics. Neurochem Res 2014; 39: 1948–1963.
    1. Hippius H. St John’s Wort (Hypericum perforatum): A herbal antidepressant. Curr Med Res Opin 1998; 14: 171–184.
    1. Ng QX, Venkatanarayanan N, Ho CY. Clinical use of Hypericum perforatum (St John’s wort) in depression: A meta-analysis. J Affect Disord 2017; 210: 211–221.
    1. Henderson L, Yue QY, Bergquist C, et al.. St John’s Wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54: 349–356.
    1. National Center for Complementary and Integrative Health. St. John’s Wort and depression: In depth, (2017, accessed 6 June 2021)
    1. Farkhondeh T, Samarghandian S, Shaterzadeh Yazdi H, et al.. The protective effects of crocin in the management of neurodegenerative diseases: A review. Am J Neurodegener Dis 2018; 7: 1–10.
    1. Yorgun MA, Rashid K, Aslanidis A, et al.. Crocin, a plant-derived carotenoid, modulates microglial reactivity. Biochem Biophys Rep 2017; 12: 245–250.
    1. Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease. Nat Rev Immunol 2018; 18: 225–242.
    1. Simpson DSA, Oliver PL. ROS generation in microglia: Understanding oxidative stress and inflammation in neurodegenerative disease. Antioxidants (Basel) 2020; 9: 743.
    1. Singh A, Kukreti R, Saso L, et al.. Oxidative stress: A key modulator in neurodegenerative diseases. Molecules 2019; 24: 1583.
    1. Clifford TJ, Warsi MJ, Burnett CA, et al.. Burning mouth in Parkinson’s disease sufferers. Gerodontology 1998; 15: 73–78.
    1. Kim JY, Kim YS, Ko I, et al.. Association between burning mouth syndrome and the development of depression, anxiety, dementia, and Parkinson disease. JAMA Otolaryngol Head Neck Surg 2020; 146: 561–569.
    1. Cobley JN, Fiorello ML, Bailey DM. 13 reasons why the brain is susceptible to oxidative stress. Redox Biol 2018; 15: 490–503.
    1. Gaforio JJ, Visioli F, Alarcón-de-la-Lastra C, et al.. Virgin olive oil and health: Summary of the III international conference on virgin olive oil and health consensus report. JAEN (Spain) 2018. Nutrients 2019; 11: 2039.
    1. Gupta S, Jawanda MK, Arora V, et al.. Role of lycopene in preventing oral diseases as a nonsurgical aid of treatment. Int J Prev Med 2015; 6: 70.
    1. Garrido M, González-Flores D, Marchena AM, et al.. A lycopene-enriched virgin olive oil enhances antioxidant status in humans. J Sci Food Agric 2013; 93: 1820–1826.
    1. Ametov AS, Barinov A, Dyck PJ, et al.. SYDNEY trial study group. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: The SYDNEY trial. Diabetes Care 2003; 26: 770–776.
    1. Ziegler D, Low PA, Litchy WJ, et al.. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: The NATHAN 1 trial. Diabetes Care 2011; 34: 2054–2060.
    1. Keith DJ, Butler JA, Bemer B, et al.. Age and gender dependent bioavailability of R- and R,S-α-lipoic acid: A pilot study. Pharmacol Res 2012; 66: 199–206.
    1. Vaughan R, Galley H, Kanakarajan S. Assessment of sleep in patients with chronic pain. BJA 2018; 120: e10.
    1. Wilhelmsen M, Amirian I, Reiter RJ, et al.. Analgesic effects of melatonin: A review of current evidence from experimental and clinical studies. J Pineal Res 2011; 51: 270–277.
    1. Hussain SA, Al-Khalifa II, Jasim NA, et al.. Adjuvant use of melatonin for treatment of fibromyalgia. J Pineal Res 2011; 50: 267–271.
    1. Vidor LP, Torres IL, De Souza ICC, et al.. Analgesic and sedative effects of melatonin in temporomandibular disorders: A double-blind, randomized, parallel-group, placebo-controlled study. J Pain Symptom Manage 2013; 46: 422–432.
    1. Ulugol A, Dokmeci D, Guray G, et al.. Antihyperalgesic, but not antiallodynic, effect of melatonin in nerve-injured neuropathic mice: Possible involvements of the L-arginine-NO pathway and opioid system. Life Sci 2006; 78: 1592–1597.
    1. Ambriz-Tututi M, Granados-Soto V. Oral and spinal melatonin reduces tactile allodynia in rats via activation of MT2 and opioid receptors. Pain 2007; 132: 273–280.
    1. Zhu C, Xu Y, Duan Y, et al.. Exogenous melatonin in the treatment of pain: A systematic review and meta-analysis. Oncotarget 2017; 8: 100582–100592.
    1. Danilov A, Kurganova J. Melatonin in chronic pain syndromes. Pain Ther 2016; 5: 1–17.
    1. Bjordal JM, Couppé C, Chow RT, et al.. A systematic review of low level laser therapy with location-specific doses for pain from chronic joint disorders. Aust J Physiother 2003; 49: 107–116.
    1. Pandeshwar P, Roa MD, Das R, et al.. Photobiomodulation in oral medicine: A review. J Investig Clin Dent 2016; 7: 114–126.
    1. Prockt AP, Takahashi A, Pagnoncelli RM. Use of low intensity laser therapy in maxillofacial surgery. Rev Port Estomatol Cir Maxilofac 2008; 49: 247–255.
    1. Nasri-Heir C, Zagury JG, Thomas D, et al.. Burning mouth syndrome: Current concepts. J Indian Prosthodont Soc 2015; 15: 300–307.
    1. Imura H, Shimada M, Yamazaki Y, et al.. Characteristic changes of saliva and taste in burning mouth syndrome patients. J Oral Pathol Med 2016; 45: 231–236.
    1. Moore RA, Derry S, Aldington D, et al.. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev 2015; 7: CD008242.
    1. Lee YC, Hong IK, Na SY, et al.. Evaluation of salivary function in patients with burning mouth syndrome. Oral Dis 2015; 21: 308–313.
    1. Fernandez-Pena C, Viana F. Targeting TRPM8 for pain relief. Open Pain J 2013; 6: 154–164.
    1. Tan Y, Wu X, Chen J, et al.. Structural and functional connectivity between the amygdala and orbital frontal cortex in burning mouth syndrome: An fMRI study. Front Psychol 2019; 10: 1700.
    1. Passard A, Attal N, Benadhira R, et al.. Effects of unilateral repetitive transcranial magnetic stimulation of the motor cortex on chronic widespread pain in fibromyalgia. Brain 2007; 130: 2661–2670.
    1. Moisset X, De Andrade DC, Bouhassira D. From pulses to pain relief: An update on the mechanisms of rTMS-induced analgesic effects. Eur J Pain 2016; 20: 689–700.
    1. López-Jornet P, Camacho-Alonso F, Leon-Espinosa S. Burning mouth syndrome, oral parafunctions, and psychological profile in a longitudinal case study. J Eur Acad Dermatol Venereol 2009; 23: 363–365.
    1. Lim JA, Choi SH, Lee WJ, et al.. Cognitive-behavioral therapy for patients with chronic pain: Implications of gender differences in empathy. Medicine (Baltimore ) 2018; 97: e10867.
    1. Hofmann SG, Asnaani A, Vonk IJ, et al.. The efficacy of cognitive behavioral therapy: A review of meta-analyses. Cognit Ther Res 2012; 36: 427–440.
    1. Sardella A, Lodi G, Tarozzi M, et al.. Acupuncture and burning mouth syndrome: A pilot study. Pain Pract 2013; 13: 627–632.
    1. Jurisic Kveisic A, Zavoreo I, Basic Kes V, et al.. The effectiveness of acupuncture versus clonazepam in patients with burning mouth syndrome. Acupunct Med 2015; 33: 289–292.
    1. Franco FR, Castro LA, Borsatto MC, et al.. Combined acupuncture and auriculotherapy in burning mouth syndrome treatment: A preliminary single-arm clinical trial. J Altern Complement Med 2017; 23: 126–134.
    1. Iris Z, Miroslav S, Vanja VB, et al. . Efficacy of acupuncture and vitamin C in burning mouth syndrome: A pilot study. Res J Pharm Biol Chem Sci 2017; 8: 26–30.
    1. Diep CP, Goddard G, Mauro G. Acupuncture improves pain and rest in burning mouth syndrome patients: A clinical cases. Dental Cadmos 2019; 87: 548--554.
    1. Scardina GA, Ruggieri A, Provenzana F, et al.. Burning mouth syndrome: Is acupuncture a therapeutic possibility? Br Dent J 2010; 209; E2.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir